Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia
X Wu, F Wang, X Yang, Y Gong, T Niu, B Chu, Y Qu… - Small, 2024 - Wiley Online Library
Acute myeloid leukemia (AML) is a common and catastrophic hematological neoplasm with
high mortality rates. Conventional therapies, including chemotherapy, hematopoietic stem …
high mortality rates. Conventional therapies, including chemotherapy, hematopoietic stem …
Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia
K Parmar, R Kundu, A Maiti, S Ball - Leukemia Research, 2024 - Elsevier
Acute myeloid leukemia with antecedent hematologic disorder (AHD-AML) and therapy
related AML (t-AML) constitute a heterogenous disease with inferior outcomes. It is often …
related AML (t-AML) constitute a heterogenous disease with inferior outcomes. It is often …
Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients
E Benedetti, G Traverso, G Pucci, R Morganti… - Frontiers in …, 2023 - frontiersin.org
Introduction Neutropenic enterocolitis (NEC) is a life-threatening complication reported in
patients with acute myeloid leukemia (AML) following chemotherapy (CHT). Intensive …
patients with acute myeloid leukemia (AML) following chemotherapy (CHT). Intensive …
TP53 Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
DA Sallman, M Stahl - Blood, 2024 - Elsevier
Despite advances in the treatment paradigm of patients with acute myeloid leukemia (AML),
TP53 mutated AML represents a molecular subgroup that has failed to improve with an …
TP53 mutated AML represents a molecular subgroup that has failed to improve with an …
MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia
D Kegyes, PS Thiagarajan, G Ghiaur - 2024 - preprints.org
Advances in molecular biology, polymerase chain reaction (PCR), and next-generation
sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a …
sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a …
CREST‐UK: Real‐world effectiveness, safety and outpatient delivery of CPX‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with …
P Mehta, V Campbell, J Maddox, Y Floisand… - British Journal of … - Wiley Online Library
Favourable outcomes with CPX‐351 versus conventional 7+ 3 were demonstrated in the
pivotal phase III trial in adults aged 60–75 years with newly diagnosed, highrisk/secondary …
pivotal phase III trial in adults aged 60–75 years with newly diagnosed, highrisk/secondary …
[HTML][HTML] Combinatorial targeting of transcriptional cyclin-dependent kinases in cancer cells
Z Wang - 2023 - helda.helsinki.fi
The process of transferring genetic information from DNA to RNA, namely gene transcription,
involves various transcription factors. Precise control of RNA polymerase II (RNAPII) at each …
involves various transcription factors. Precise control of RNA polymerase II (RNAPII) at each …